Webinar presenter, Fred R. Hirsch MD, PhD, FASCO, Executive Director, Center for Thoracic Oncology, Professor of Medicine and Pathology, Joe Lowe and Louis Price Professor of Medicine, Associate Director, Tisch Cancer Institute, discusses how personalized medicine has revolutionized the treatment of patients with advanced non-small cell lung cancer (aNSCLC) with non-squamous histology, the emerging clinical relevance of HER2 (ERBB2) mutations in aNSCLC in context with other HER2 alterations, and the best practices for identifying HER2 alterations in aNSCLC with a practical focus on multidisicplinary collaboration. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast May 17, 2022. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast May 17, 2022.

CAP TODAY does not endorse any of the products or services named within.
This program is not CME accredited and no CME credit will be provided.
This webinar is sponsored by Daiichi Sankyo, Inc. and AstraZeneca.
The speaker is receiving compensation for this presentation.
©2022 Daiichi Sankyo, Inc. and AstraZeneca. All rights reserved. PP-US-8201a-1226. Last Updated 04/22

свернуть